Guggenheim Capital LLC Celldex Therapeutics, Inc. Transaction History
Guggenheim Capital LLC
- $10.6 Billion
- Q1 2025
A detailed history of Guggenheim Capital LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 24,783 shares of CLDX stock, worth $518,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,783
Previous 23,797
4.14%
Holding current value
$518,212
Previous $601,000
25.29%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CLDX
# of Institutions
188Shares Held
69.3MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$175 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$136 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$98.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$81.5 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$78.5 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $978M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...